ePT--the Electronic Newsletter of Pharmaceutical Technology, May 24, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, May 24, 2012
News
Human Genome Sciences Rejects GlaxoSmithKline's $2.6 Billion Offer
By Jennifer Markarian
Human Genome Sciences rejects GlaxoSmithKline offer to acquire the company and issues a poison pill to prevent a takeover.
PDA Releases Technical Report on TBA and TCA Odors and Taints
By Susan Haigney
The Parenteral Drug Association has released guidance on the detection and mitigation of 2,4,6-tribromoanisole and 2,4,6-trichloroanisole taints and odors in pharmaceutical and healthcare products.
UK Condemns Parallel Trade
By Stephanie Sutton
A recent report from the UK's All Party Pharmacy Group has attributed shortages of prescription medicines in the UK to parallel trade and is calling for urgent action.
Week of May 21, 2012: FDA Approves BMS's New Bulk Biologics Manufacturing Facility; SGS Acquires Vitrology; and More
GSK Agrees to Acquire Cellzome; Patheon Restructures; and More.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
18%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here